Advertisement

Neurotherapeutics

, Volume 7, Issue 3, pp 264–274 | Cite as

Fragile X: Leading the way for targeted treatments in autism

  • Lulu W. WangEmail author
  • Elizabeth Berry-Kravis
  • Randi J. Hagerman
Review Article

Summary

Two different mutations in the FMR1 gene may lead to autism. The full mutation, with >200 CGG repeats in the 5′ end of FMR1, leads to hypermethylation and transcriptional silencing of FMR1, resulting in absence or deficiency of the protein product, FMRP. Deficiency of FMRP in the brain causes fragile X syndrome (FXS). Autism occurs in approximately 30% of those with FXS, and pervasive developmental disorders-not otherwise specified occur in an additional 30%. FMRP is an RNA binding protein that modulates receptor-mediated dendritic translation; deficiency leads to dysregulation of many proteins important for synaptic plasticity. Group I metabotropic glutamate receptor (mGluR1/5) activated translation is upregulated in FXS, and new targeted treatments that act on this system include mGluR5 antagonists and GABA agonists, which may reverse the cognitive and behavioral deficits in FXS. Matrix metalloproteinase 9 (MMP-9) is one of the proteins elevated in FXS, and minocycline reduces excess MMP-9 activity in the Fmr1 knockout mouse model of FXS. Both minocycline and mGluR5 antagonists are currently being evaluated in patients with FXS through controlled treatment trials. The premutation (55–200 CGG repeats) may also contribute to the mechanism of autism in approximately 10% of males and 2–3% of females. Premutations with <150 repeats exert cellular effects through a different molecular mechanism, one that involves elevated levels of FMR1 mRNA, CGG-mediated toxicity to neurons, early cell death, and fragile X-associated tremor/ataxia syndrome. In those with large premutations (150–200), lowered levels of FMRP also occur.

Key Words

Fragile X syndrome autism ASD mGluR GABA treatment animal model 
Download to read the full article text

References

  1. 1.
    Hagerman RJ, Rivera SM, Hagerman PJ. The fragile X family of disorders: a model for autism and targeted treatments. Curr Pediatr Rev 2008;4: 40–52.CrossRefGoogle Scholar
  2. 2.
    Reddy KS. Cytogenetic abnormalities and fragile-X syndrome in autism spectrum disorder. BMC Med Genet 2005;6: 3.PubMedCrossRefGoogle Scholar
  3. 3.
    van Karnebeek CD, Jansweijer MC, Leenders AG, Offringa M, Hennekam RC. Diagnostic investigations in individuals with mental retardation: a systematic literature review of their usefulness. Eur J Hum Genet 2005;13: 6–25.PubMedCrossRefGoogle Scholar
  4. 4.
    Femandez-Carvajal I, Walichiewicz P, Xiaosen X, Pan R, Hagerman PJ, Tassone F. Screening for expanded alleles of the FMR1 gene in blood spots from newborn males in a Spanish population. J Mol Diagn 2009;11: 324–329.CrossRefGoogle Scholar
  5. 5.
    Hagerman PJ. The fragile X prevalence paradox [Erratum in: J Med Genet 2008;45:768]. J Med Genet 2008;45: 498–499.PubMedCrossRefGoogle Scholar
  6. 6.
    Dombrowski C, Lévesque S, Morel ML, Rouillard P, Morgan K, Rousseau F. Premutation and intermediate-size FMR1 alleles in 10 572 males from the general population: loss of an AGG interruption is a late event in the generation of fragile X syndrome alleles. Hum Mol Genet 2002;11: 371–378.PubMedCrossRefGoogle Scholar
  7. 7.
    Verkerk AJ, Pieretti M, Sutcliffe JS, et al. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome. Cell 1991;65: 905–914.PubMedCrossRefGoogle Scholar
  8. 8.
    Qin M, Kang J, Burlin TV, Jiang C, Smith CB. Postadolescent changes in regional cerebral protein synthesis: an in vivo study in the FMR1 null mouse. J Neurosci 2005;25: 5087–5095.PubMedCrossRefGoogle Scholar
  9. 9.
    Bassell GJ, Warren ST. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008;60: 201–214.PubMedCrossRefGoogle Scholar
  10. 10.
    Tassone F, Hagerman RJ, Iklé DN, et al. FMRP expression as a potential prognostic indicator in fragile X syndrome. Am J Med Genet 1999;84: 250–261.PubMedCrossRefGoogle Scholar
  11. 11.
    Loesch DZ, Huggins RM, Hagerman RJ. Phenotypic variation and FMRP levels in fragile X. Ment Retard Dev Disabil Res Rev 2004;10: 31–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Rogers SJ, Wehner DE, Hagerman R. The behavioral phenotype in fragile X: symptoms of autism in very young children with fragile X syndrome, idiopathic autism, and other developmental disorders. J Dev Behav Pediatr 2001;22: 409–417.PubMedGoogle Scholar
  13. 13.
    Kaufmann WE, Cortell R, Kau AS, et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Genet 2004;129A: 225–234.PubMedCrossRefGoogle Scholar
  14. 14.
    Loesch DZ, Bui QM, Dissanayake C, et al. Molecular and cognitive predictors of the continuum of autistic behaviours in fragile X. Neurosci Biobehav Rev 2007;31: 315–326.PubMedCrossRefGoogle Scholar
  15. 15.
    Garcia-Nonell C, Ratera ER, Harris S, et al. Secondary medical diagnosis in fragile X syndrome with and without autism spectrum disorder. Am J Med Genet A 2008;146A: 1911–1916.PubMedCrossRefGoogle Scholar
  16. 16.
    de Vries BB, Wiegers AM, Smits AP, et al. Mental status of females with an FMR1 gene full mutation. Am J Hum Genet 1996;58: 1025–1032.PubMedGoogle Scholar
  17. 17.
    Bennetto L, Pennington BF. Neuropsychology. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns Hopkins University Press, 2002: 206–248.Google Scholar
  18. 18.
    Hagerman RJ. Physical and behavioral phenotype. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns Hopkins University Press, 2002: 3–109.Google Scholar
  19. 19.
    Cronister A, Schreiner R, Wittenberger M, Amiri K, Harris K, Hagerman RJ. Heterozygous fragile X female: historical, physical, cognitive, and cytogenetic features. Am J Med Genet 1991;38: 269–274.PubMedCrossRefGoogle Scholar
  20. 20.
    Sullivan AK, Marcus M, Epstein MP, et al. Association of FMR1 repeat size with ovarian dysfunction. Hum Reprod 2005;20: 402–412.PubMedCrossRefGoogle Scholar
  21. 21.
    Wittenberger MD, Hagerman RJ, Sherman SL, et al. The FMR1 premutation and reproduction. Fertil Steril 2007;87: 456–465.PubMedCrossRefGoogle Scholar
  22. 22.
    Tassone F, Hagerman RJ, Taylor AK, Gane LW, Godfrey TE, Hagerman PJ. Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome. Am J Hum Genet 2000;66: 6–15.PubMedCrossRefGoogle Scholar
  23. 23.
    Hagerman RJ. Fragile X Syndrome. In: Cassidy SB, Allanson JE, editors. Management of genetic syndromes. 3rd ed. New York: Wiley & Sons, 2010: 397–411.Google Scholar
  24. 24.
    Jacquemont S, Hagerman RJ, Leehey MA, et al. Penetrance of the fragile X-associated tremor/ataxia syndrome in a premutation carrier population. JAMA 2004;291: 460–469.PubMedCrossRefGoogle Scholar
  25. 25.
    Hagerman RJ, Leavitt BR, Farzin F, et al. Fragile-X-associated tremor/ataxia syndrome (FXTAS) in females with the FMR1 premutation. Am J Hum Genet 2004;74: 1051–1056.PubMedCrossRefGoogle Scholar
  26. 26.
    Coffey SM, Cook K, Tartaglia N, et al. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A 2008;146A: 1009–1016.PubMedCrossRefGoogle Scholar
  27. 27.
    Rodriguez-Revenga L, Madrigal I, Alegret M, Santos M, Milà M. Evidence of depressive symptoms in fragile-X syndrome premutated females. Psychiatr Genet 2008;18: 153–155.PubMedCrossRefGoogle Scholar
  28. 28.
    Arocena DG, Iwahashi CK, Won N, et al. Induction of inclusion formation and disruption of lamin A/C structure by premutation CGG-repeat RNA in human cultured neural cells. Hum Mol Genet 2005;14: 3661–3671.PubMedCrossRefGoogle Scholar
  29. 29.
    Garcia-Arocena D, Yang JE, Brouwer JR, et al. Fibroblast phenotype in male carriers of FMR1 premutation alleles. Hum Mol Genet 2010;19: 299–312.PubMedCrossRefGoogle Scholar
  30. 30.
    Adams JS, Adams PE, Nguyen D, et al. Volumetric brain changes in females with fragile X-associated tremor/ataxia syndrome (FXTAS). Neurology 2007;69: 851–859.PubMedCrossRefGoogle Scholar
  31. 31.
    Greco CM, Berman RF, Martin RM, et al. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 2006;129: 243–255.PubMedCrossRefGoogle Scholar
  32. 32.
    Greco CM, Soontrapomchai K, Wirojanan J, Gould JE, Hagerman PJ, Hagerman RJ. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol 2007;177: 1434–1437.PubMedCrossRefGoogle Scholar
  33. 33.
    Gokden M, Al-Hinti JT, Harik SI. Peripheral nervous system pathology in fragile X tremor/ataxia syndrome (FXTAS). Neuropathology 2009;29: 280–284.PubMedCrossRefGoogle Scholar
  34. 34.
    Chen Y, Tassone F, Berman RF, et al. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 2010;19: 196–208.PubMedCrossRefGoogle Scholar
  35. 35.
    Farzin F, Perry H, Hessl D, et al. Autism spectrum disorders and attention-deficit/hyperactivity disorder in boys with the fragile X premutation. J Dev Behav Pediatr 2006;27(2 Suppl): S137-S144.PubMedCrossRefGoogle Scholar
  36. 36.
    Aziz M, Stathopulu E, Callias M, et al. Clinical features of boys with fragile X premutations and intermediate alleles. Am J Med Genet B Neuropsychiatr Genet 2003;121B: 119–127.PubMedCrossRefGoogle Scholar
  37. 37.
    Bailey DB Jr, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A 2008;146A: 2060–2069.PubMedCrossRefGoogle Scholar
  38. 38.
    Hunter JE, Allen EG, Abramowitz A, et al. No evidence for a difference in neuropsychological profile among carriers and non-carriers of the FMR1 premutation in adults under the age of 50. Am J Hum Genet 2008;83: 692–702.PubMedCrossRefGoogle Scholar
  39. 39.
    Grigsby J, Brega AG, Engle K, et al. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 2008;22: 48–60.PubMedCrossRefGoogle Scholar
  40. 40.
    Cornish KM, Kogan CS, Li L, Turk J, Jacquemont S, Hagerman RJ. Lifespan changes in working memory in fragile X premutation males. Brain Cogn 2009;69: 551–558.PubMedCrossRefGoogle Scholar
  41. 41.
    Moore CJ, Daly EM, Schmitz N, et al. A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia 2004;42: 1934–1947.PubMedCrossRefGoogle Scholar
  42. 42.
    Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J Autism Dev Disord 2007;37: 738–747.PubMedCrossRefGoogle Scholar
  43. 43.
    Bourgeois J, Seritan A, Casillas E, et al. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry (in press).Google Scholar
  44. 44.
    Roberts JE, Bailey DB Jr, Mankowski J, et al. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet B Neuropsychiatr Genet 2009;150B: 130–139.PubMedCrossRefGoogle Scholar
  45. 45.
    Bourgeois JA, Coffey SM, Rivera SM, et al. A review of fragile X premutation disorders: expanding the psychiatric perspective. J Clin Psychiatry 2009;70: 852–862.PubMedCrossRefGoogle Scholar
  46. 46.
    Brouwer JR, Severijnen E, de Jong FH, et al. Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology 2008;33: 863–873.PubMedCrossRefGoogle Scholar
  47. 47.
    Adams PE, Adams JS, Nguyen DV, et al. Psychological symptoms correlate with reduced hippocampal volume in fragile X premutation carriers. Am J Med Genet B Neuropsychiatr Genet 2010;153B(3): 775–785.Google Scholar
  48. 48.
    Miller LJ, McIntosh DN, McGrath J, et al. Electrodermal responses to sensory stimuli in individuals with fragile X syndrome: a preliminary report. Am J Med Genet 1999;83: 268–279.PubMedCrossRefGoogle Scholar
  49. 49.
    Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994;24: 659–685.PubMedCrossRefGoogle Scholar
  50. 50.
    Lord C, Rutter M, DiLavore PC, Risi S. Autism Diagnostic Observation Schedule. Los Angeles, CA: Western Psychological Services, 1999.Google Scholar
  51. 51.
    Harris SW, Hessl D, Goodlin-Jones B, et al. Autism profiles of males with fragile X syndrome. Am J Ment Retard 2008;113: 427–438.PubMedCrossRefGoogle Scholar
  52. 52.
    Hagerman RJ, Jackson AW 3rd, Levitas A, Rimland B, Braden M. An analysis of autism in fifty males with the fragile X syndrome. Am J Med Genet A 1986;23: 359–374.CrossRefGoogle Scholar
  53. 53.
    Bailey DB Jr, Mesibov GB, Hatton DD, Clark RD, Roberts JE, Mayhew L. Autistic behavior in young boys with fragile X syndrome. J Autism Dev Disord 1998;28: 499–508.PubMedCrossRefGoogle Scholar
  54. 54.
    Baumgardner TL, Reiss AL, Freund LS, Abrams MT. Specification of the neurobehavioral phenotype in males with fragile X syndrome. Pediatrics 1995;95: 744–752.PubMedGoogle Scholar
  55. 55.
    Kerby DS, Dawson BL. Autistic features, personality, and adaptive behavior in males with the fragile X syndrome and no autism. Am J Ment Retard 1994;98: 455–462.PubMedGoogle Scholar
  56. 56.
    Merenstein SA, Sobesky WE, Taylor AK, Riddle JE, Tran HX, Hagerman RJ. Molecular-clinical correlations in males with an expanded FMR1 mutation. Am J Med Genet 1996;64: 388–394.PubMedCrossRefGoogle Scholar
  57. 57.
    Hall SS, Lightbody AA, Reiss AL. Compulsive, self-injurious, and autistic behavior in children and adolescents with fragile X syndrome. Am J Ment Retard 2008;113: 44–53.PubMedCrossRefGoogle Scholar
  58. 58.
    Bailey A, Bolton P, Butler L, et al. Prevalence of the fragile X anomaly amongst autistic twins and singletons. J Child Psychol Psychiatry 1993;34: 673–688.PubMedCrossRefGoogle Scholar
  59. 59.
    Bailey A, Phillips W, Rutter M. Autism: towards an integration of clinical, genetic, neuropsychological, and neurobiological perspectives. J Child Psychol Psychiatry 1996;37: 89–126.PubMedCrossRefGoogle Scholar
  60. 60.
    Dykens EM, Volkmar FR. Medical conditions associated with autism. In: Cohen DJ, Volkmar FR, editors. Handbook of autism and pervasive developmental disorders. 2nd ed. New York: John Wiley & Sons, 1997: 388–410.Google Scholar
  61. 61.
    Nowicki ST, Tassone F, Ono MY, et al. The Prader-Willi phenotype of fragile X syndrome. J Dev Behav Pediatr 2007;28: 133–138.PubMedCrossRefGoogle Scholar
  62. 62.
    Roberts J, Price J, Barnes E, et al. Receptive vocabulary, expressive vocabulary, and speech production of boys with fragile X syndrome in comparison to boys with Down syndrome. Am J Ment Retard 2007;112: 177–193.PubMedCrossRefGoogle Scholar
  63. 63.
    Kau AS, Tierney E, Bukelis I, et al. Social behavior profile in young males with fragile X syndrome: characteristics and specificity. Am J Med Genet 2004;126A: 9–17.PubMedCrossRefGoogle Scholar
  64. 64.
    Hatton DD, Sideris J, Skinner M, et al. Autistic behavior in children with fragile X syndrome: prevalence, stability, and the impact of FMRP. Am J Med Genet A 2006;140A: 1804–1813.PubMedCrossRefGoogle Scholar
  65. 65.
    Lewis P, Abbeduto L, Murphy M, et al. Cognitive, language and social-cognitive skills of individuals with fragile X syndrome with and without autism. J Intellect Disabil Res 2006;50: 532–545.PubMedCrossRefGoogle Scholar
  66. 66.
    Chiu S, Wegelin JA, Blank J, et al. Early acceleration of head circumference in children with fragile X syndrome and autism. J Dev Behav Pediatr 2007;28: 31–35.PubMedCrossRefGoogle Scholar
  67. 67.
    Courchesne E, Carper R, Akshoomoff N. Evidence of brain overgrowth in the first year of life in autism. JAMA 2003;290: 337–344.PubMedCrossRefGoogle Scholar
  68. 68.
    Butler MG, Dasouki MJ, Zhou XP, et al. Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 2005;42: 318–321.PubMedCrossRefGoogle Scholar
  69. 69.
    Reiss AL, Freund L, Tseng JE, Joshi PK. Neuroanatomy in fragile X females: the posterior fossa. Am J Hum Genet 1991;49: 279–288.PubMedGoogle Scholar
  70. 70.
    Mostofsky SH, Mazzocco MM, Aakalu G, Warsofsky IS, Denckla MB, Reiss AL. Decreased cerebellar posterior vermis size in fragile X syndrome: correlation with neurocognitive performance. Neurology 1998;50: 121–130.PubMedGoogle Scholar
  71. 71.
    Murakami JW, Courchesne E, Press GA, Yeung-Courchesne R, Hesselink JR. Reduced cerebellar hemisphere size and its relationship to vermal hypoplasia in autism. Arch Neurol 1989;46: 689–694.PubMedGoogle Scholar
  72. 72.
    Ciesielski KT, Harris RJ, Hart BL, Pabst HF. Cerebellar hypoplasia and frontal lobe cognitive deficits in disorders of early childhood. Neuropsychologia 1997;35: 643–655.PubMedCrossRefGoogle Scholar
  73. 73.
    Pierce K, Courchesne E. Evidence for a cerebellar role in reduced exploration and stereotyped behavior in autism. Biol Psychiatry 2001;49: 655–664.PubMedCrossRefGoogle Scholar
  74. 74.
    Mazzocco MM, Kates WR, Baumgardner TL, Freund LS, Reiss AL. Autistic behaviors among girls with fragile X syndrome. J Autism Dev Disord 1997;27: 415–435.PubMedCrossRefGoogle Scholar
  75. 75.
    Van Essen DC, Maunsell HH. Hierarchical organization of the functional streams in the visual cortex. Trends Neurosci 1983;6: 370–375.CrossRefGoogle Scholar
  76. 76.
    Sagi D, Julesz B. “Where” and “what” in vision. Science 1985;228: 1217–1219.PubMedCrossRefGoogle Scholar
  77. 77.
    Kogan CS, Boutet I, Cornish KM, et al. Differential impact of the FMR1 gene on visual processing in fragile X syndrome. Brain 2004;127: 591–601.PubMedCrossRefGoogle Scholar
  78. 78.
    Spencer J, O’Brien J, Riggs K, Braddick O, Atkinson J, Wattam-Bell J. Motion processing in autism: evidence for a dorsal stream deficiency. Neuroreport 2000;11: 2765–2767.PubMedCrossRefGoogle Scholar
  79. 79.
    Bertone A, Mottron L, Jelenic P, Faubert J. Motion perception in autism: a “complex” issue. J Cogn Neurosci 2003;15: 218–225.PubMedCrossRefGoogle Scholar
  80. 80.
    Blake R, Turner LM, Smoski MJ, Pozdol SL, Stone WL. Visual recognition of biological motion is impaired in children with autism. Psychol Sci 2003;14: 151–157.PubMedCrossRefGoogle Scholar
  81. 81.
    Hazlett HC, Poe MD, Lightbody AA, et al. Teasing apart the heterogeneity of autism: same behavior, different brains in toddlers with fragile X syndrome and autism. J Neurodev Disord 2009;1: 81–90.PubMedCrossRefGoogle Scholar
  82. 82.
    Hagerman RJ, Miller LJ, McGrath-Clarke J, et al. Influence of stimulants on electrodermal studies in fragile X syndrome. Microsc Res Tech 2002;57: 168–173.PubMedCrossRefGoogle Scholar
  83. 83.
    Roberts JE, Boccia ML, Bailey DB Jr, Hatton DD, Skinner M. Cardiovascular indices of physiological arousal in boys with fragile X syndrome. Dev Psychobiol 2001;39: 107–123.PubMedCrossRefGoogle Scholar
  84. 84.
    Roberts JE, Boccia ML, Hatton DD, Skinner ML, Sideris J. Temperament and vagal tone in boys with fragile X syndrome. J Dev Behav Pediatr 2006;27: 193–201.PubMedCrossRefGoogle Scholar
  85. 85.
    Boccia ML, Roberts JE. Behavior and autonomic nervous system function assessed via heart period measures: the case of hyperarousal in boys with fragile X syndrome. Behav Res Methods, Instrum Comput 2000;32: 5–10.CrossRefGoogle Scholar
  86. 86.
    Cohen IL. A theoretical analysis of the role of hyperarousal in the learning and behavior of fragile X males. Ment Retard Dev Disabil Res Rev 1995;1: 286–291.CrossRefGoogle Scholar
  87. 87.
    Frankland PW, Wang Y, Rosner B, et al. Sensorimotor gating abnormalities in young males with fragile X syndrome and FMR1-knockout mice. Mol Psychiatry 2004;9: 417–425.PubMedCrossRefGoogle Scholar
  88. 88.
    Hessl D, Berry-Kravis E, Cordeiro L, et al. Prepulse inhibition in fragile X syndrome: feasibility, reliability, and implications for treatment. Am J Med Genet B Neuropsychiatr Genet 2009;150B: 545–53.PubMedCrossRefGoogle Scholar
  89. 89.
    Perry W, Minassian A, Lopez B, Maron L, Lincoln A. Sensorimotor gating deficits in adults with autism. Biol Psychiatry 2007;61: 482–486.PubMedCrossRefGoogle Scholar
  90. 90.
    Postma P, Kumari V, Hines M, Gray JA. The relationship between prepulse detection and prepulse inhibition of the acoustic startle reflex. Psychophysiology 2001;38: 377–382.PubMedCrossRefGoogle Scholar
  91. 91.
    Greenough WT, Klintsova AY, Irwin SA, Galvez R, Bates KE, Weiler IJ. Synaptic regulation of protein synthesis and the fragile X protein. Proc Natl Acad Sci U S A 2001;98: 7101–7106.PubMedCrossRefGoogle Scholar
  92. 92.
    McBride SM, Choi CH, Wang Y, et al. Pharmacological rescue of synaptic plasticity, courtship behavior, and mushroom body defects in a Drosophila model of fragile X syndrome. Neuron 2005;45: 753–764.PubMedCrossRefGoogle Scholar
  93. 93.
    Bakker CE, Oostra BA. Understanding fragile X syndrome: insights from animal models. Cytogenet Genome Res 2003;100: 111–123.PubMedCrossRefGoogle Scholar
  94. 94.
    Zhang YQ, Bailey AM, Matthies HJ, et al. Drosophila fragile X-related gene regulates the MAP1B homolog Futsch to control synaptic structure and function. Cell 2001;107: 591–603.PubMedCrossRefGoogle Scholar
  95. 95.
    Dockendorff TC, Su HS, McBride SM, et al. Drosophila lacking dfmr1 activity show defects in circadian output and fail to maintain courtship interest. Neuron 2002;34: 973–984.PubMedCrossRefGoogle Scholar
  96. 96.
    Morales J, Hiesinger PR, Schroeder AJ, et al. Drosophila fragile X protein, DFXR, regulates neuronal morphology and function in the brain. Neuron 2002;34: 961–972.PubMedCrossRefGoogle Scholar
  97. 97.
    Lee A, Li W, Xu K, Bogert BA, Su K, Gao FB. Control of dendritic development by the Drosophila fragile X-related gene involves the small GTPase Rac1. Development 2003;130: 5543–5552.PubMedCrossRefGoogle Scholar
  98. 98.
    Dolen G, Osterweil E, Rao BS, et al. Collection of fragile X syndrome in mice. Neuron 2007;56: 955–962.PubMedCrossRefGoogle Scholar
  99. 99.
    Bear MF, Dolen G, Osterweil E, Nagarajan N. Fragile X: translation in action. Neuropsychopharmacology 2008;33: 84–87.PubMedCrossRefGoogle Scholar
  100. 100.
    Penagarikano O, Mulle JG, Warren ST. The pathophysiology of fragile X syndrome. Annu Rev Genomics Hum Genet 2007;8: 109–129.PubMedCrossRefGoogle Scholar
  101. 101.
    Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. Trends Neurosci 2004;27: 370–377.PubMedCrossRefGoogle Scholar
  102. 102.
    Bear MF. Therapeutic implications of the mGluR theory of fragile X mental retardation. Genes Brain Behav 2005;4: 393–398.PubMedCrossRefGoogle Scholar
  103. 103.
    Comery TA, Harris JB, Willems PJ, et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. Proc Natl Acad Sci U S A 1997;94: 5401–5404.PubMedCrossRefGoogle Scholar
  104. 104.
    Nimchinsky EA, Oberlander AM, Svoboda K. Abnormal development of dendritic spines in FMR1 knock-out mice. J Neurosci 2001;21: 5139–5146.PubMedGoogle Scholar
  105. 105.
    Irwin SA, Patel B, Idupulapati M, et al. Abnormal dendritic spine characteristics in the temporal and visual cortices of patients with fragile-X syndrome: a quantitative examination. Am J Med Genet A 2001;98: 161–167.CrossRefGoogle Scholar
  106. 106.
    Knott GW, Holtmaat A, Wilbrecht L, Welker E, Svoboda K. Spine growth precedes synapse formation in the adult neocortex in vivo. Nat Neurosci 2006;9: 1117–1124.PubMedCrossRefGoogle Scholar
  107. 107.
    Linden DJ. Input-specific induction of cerebellar long-term depression does not require presynaptic alteration. Learn Mem 1994;1: 121–128.PubMedGoogle Scholar
  108. 108.
    Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res Brain Res Rev 1999;29: 83–120.PubMedCrossRefGoogle Scholar
  109. 109.
    Huber KM, Gallagher SM, Warren ST, Bear MF. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc Natl Acad Sci U S A 2002;99: 7746–7750.PubMedCrossRefGoogle Scholar
  110. 110.
    Zheng F, Gallagher JP. Metabotropic glutamate receptors are required for the induction of long-term potentiation. Neuron 1992;9: 163–172.PubMedCrossRefGoogle Scholar
  111. 111.
    Fendt M, Schmid S. Metabotropic glutamate receptors are involved in amygdaloid plasticity. Eur J Neurosci 2002;15: 1535–1541.PubMedCrossRefGoogle Scholar
  112. 112.
    Koekkoek SK, Yamaguchi K, Milojkovic BA, et al. Deletion of FMR1 in Purkinje]ells enhances parallel fiber LTD, enlarges spines, and attenuates cerebellar eyelid conditioning in fragile X syndrome. Neuron 2005;47: 339–352.PubMedCrossRefGoogle Scholar
  113. 113.
    Nakamoto M, Nalavadi V, Epstein MP, Narayanan U, Bassell GJ, Warren ST. Fragile X mental retardation protein deficiency leads to excessive mGluR5-dependent internalization of AMPA receptors. Proc Natl Acad Sci U S A 2007;104: 15537–15542.PubMedCrossRefGoogle Scholar
  114. 114.
    Irwin SA, Galvez R, Weiler IJ, Beckel-Mitchener A, Greenough WT. Brain structure and functions of FMR1 protein. In: Hagerman RJ, Hagerman PJ, editors. Fragile X syndrome: diagnosis, treatment, and research. 3rd ed. Baltimore: Johns Hopkins University Press, 2002: 191–205.Google Scholar
  115. 115.
    Beckel-Mitchener A, Greenough WT. Correlates across the structural, functional, and molecular phenotypes of fragile X syndrome. Ment Retard Dev Disabil Res Rev 2004;10: 53–59.PubMedCrossRefGoogle Scholar
  116. 116.
    Chuang SC, Zhao W, Bauchwitz R, Yan Q, Bianchi R, Wong RK. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J Neurosci 2005;25: 8048–8055.PubMedCrossRefGoogle Scholar
  117. 117.
    Gasparini F, Lingenhohl K, Stoehr N, et al. 2-Methyl-6-(phenyl-ethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999;38: 1493–1503.PubMedCrossRefGoogle Scholar
  118. 118.
    Yan QJ, Rammal M, Tranfaglia M, Bauchwitz RP. Suppression of two major fragile X syndrome mouse model phenotypes by the mGluR5 antagonist MPEP. Neuropharmacology 2005;49: 1053–1066.PubMedCrossRefGoogle Scholar
  119. 119.
    de Vrij FM, Levenga J, van der Linde HC, et al. Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice. Neurobiol Dis 2008;31: 127–132.PubMedCrossRefGoogle Scholar
  120. 120.
    Paredes RG, Agmo A. GABA and behavior: the role of receptor subtypes [Erratum in: Neurosci Biobehav Rev 1992;16:425]. Neurosci Biobehav Rev 1992;16: 145–170.PubMedCrossRefGoogle Scholar
  121. 121.
    Mihalek RM, Banerjee PK, Korpi ER, et al. Attenuated sensitivity to neuroactive steroids in γ-aminobutyrate type A receptor delta subunit knockout mice. Proc Natl Acad Sci U S A 1999;96: 12905–12910.PubMedCrossRefGoogle Scholar
  122. 122.
    Carter RB, Wood PL, Wieland S, et al. Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acidA receptor. J Pharmacol Exp Ther 1997;280: 1284–1295.PubMedGoogle Scholar
  123. 123.
    Miyashiro KY, Beckel-Mitchener A, Purk TP, et al. RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice. Neuron 2003;37: 417–431.PubMedCrossRefGoogle Scholar
  124. 124.
    D’Hulst C, De Geest N, Reeve SP, et al. Decreased expression of the GABAA receptor in fragile X syndrome. Brain Res 2006;1121: 238–245.PubMedCrossRefGoogle Scholar
  125. 125.
    Gantois I, Vandesompele J, Speleman F, et al. Expression profiling suggests underexpression of the GABAA receptor subunit delta in the fragile X knockout mouse model. Neurobiol Dis 2006;21: 346–357.PubMedCrossRefGoogle Scholar
  126. 126.
    Chang S, Bray SM, Li Z, et al. Identification of small molecules rescuing fragile X syndrome phenotypes in Drosophila. Nat Chem Biol 2008;4: 256–263.PubMedCrossRefGoogle Scholar
  127. 127.
    Isaacson JS, Hille B. GABAB-mediated presynaptic inhibition of excitatory transmission and synaptic vesicle dynamics in cultured hippocampal neurons. Neuron 1997;18: 143–152.PubMedCrossRefGoogle Scholar
  128. 128.
    Sohn JW, Lee D, Cho H, et al. Receptor-specific inhibition of GABAB-activated K+ currents by muscarinic and metabotropic glutamate receptors in immature rat hippocampus. J Physiol 2007;580: 411–422.PubMedCrossRefGoogle Scholar
  129. 129.
    Primrose DA. Treatment of self-injurious behaviour with a GABA (γ-aminobutyric acid) analogue. J Ment Defic Res 1979;23: 163–173.PubMedGoogle Scholar
  130. 130.
    Paylor R. Pharmacological modification of behavioral responses in the fragile X mouse model. Proc Int Fragile X Conf 11th 2008;11: 1052 (abstract). Available at http://www.fragilex.org/ html/2008_proceedings.htm.Google Scholar
  131. 131.
    Pacey LK, Heximer SP, Hampson DR. Increased GABAB receptor-mediated signaling reduces the susceptibility of fragile X knockout mice to audiogenic seizures. Mol Pharmacol 2009;76: 18–24.PubMedCrossRefGoogle Scholar
  132. 132.
    Porter RH, Jaeschke G, Spooren W, et al. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 2005;315: 711–721.PubMedCrossRefGoogle Scholar
  133. 133.
    Beny-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009;46: 266–271.CrossRefGoogle Scholar
  134. 134.
    Hagerman RJ, Beny-Kravis E, Kaufmann WE, et al. Advances in the treatment of fragile X syndrome. Pediatrics 2009;123: 378–390.PubMedCrossRefGoogle Scholar
  135. 135.
    Beny-Kravis E, Sumis A, Hervey C, et al. Open-label treatment trial of lithium to target the underlying defect in fragile X syndrome. J Dev Behav Pediatr 2008;29: 293–302.CrossRefGoogle Scholar
  136. 136.
    Li J, Pelletier MR, Perez Velazquez JL, Carlen PL. Reduced cortical synaptic plasticity and GluR1 expression associated with fragile X mental retardation protein deficiency. Mol Cell Neurosci 2002;19: 138–151.PubMedCrossRefGoogle Scholar
  137. 137.
    Lauterborn JC, Rex CS, Kramár E, et al. Brain-derived neurotrophic factor rescues synaptic plasticity in a mouse model of fragile X syndrome. J Neurosci 2007;27: 10685–10694.PubMedCrossRefGoogle Scholar
  138. 138.
    Berry-Kravis E, Krause SE, Block SS, et al. Effect of CX516, an AMPA-modulating compound, on cognition and behavior in fragile X syndrome: a controlled trial. J Child Adolesc Psychopharmacol 2006;16: 525–540.PubMedCrossRefGoogle Scholar
  139. 139.
    Bilousova TV, Rusakov DA, Ethell DW, Ethell IM. Matrix metalloproteinase-7 disrupts dendritic spines in hippocampal neurons through NMDA receptor activation. J Neurochem 2006;97: 44–56.PubMedCrossRefGoogle Scholar
  140. 140.
    Bilousova TV, Dansie L, Ngo M, et al. Minocycline promotes dendritic spine maturation and improves behavioural performance in the fragile X mouse model. J Med Genet 2009;46: 94–102.PubMedCrossRefGoogle Scholar
  141. 141.
    Utari A, Chonchaiya W, Rivera SM, et al. Side effects of minocycline treatment in patients with fragile X syndrome and exploration of outcome measures. Am J Intellect Dev Disabil (in press).Google Scholar
  142. 142.
    McCracken JT, McGough J, Shah B, et al. Risperidone in children with autism and serious behavioral problems. N Engl J Med 2002;347: 314–321.PubMedCrossRefGoogle Scholar
  143. 143.
    Aman MG, Gharabawi GM; Special Topic Advisory Panel on Transitioning to Risperidone Therapy in Patients With Mental Retardation and Developmental Disabilities. Treatment of behavior disorders in mental retardation: report on transitioning to atypical antipsychotics, with an emphasis on risperidone. J Clin Psychiatry 2004;65: 1197–1210.PubMedCrossRefGoogle Scholar
  144. 144.
    Owen R, Sikich L, Marcus RN, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics 2009;124: 1533–1540.PubMedCrossRefGoogle Scholar
  145. 145.
    Erickson CA, Kohn AE, Diener JT, Stigler KA, Posey DJ, McDougle CJ. A prospective, 12-week open-label study of aripiprazole in fragile X syndrome. Proc Int Fragile X Conf 11th 2008;11: 1065–1100. Available at http://www.fragilex.org/ html/2008_proceedings.htm.Google Scholar

Copyright information

© Springer 2010

Authors and Affiliations

  • Lulu W. Wang
    • 1
    • 2
    Email author
  • Elizabeth Berry-Kravis
    • 3
    • 4
    • 5
  • Randi J. Hagerman
    • 1
    • 2
  1. 1.Department of PediatricsUniversity of California, Davis, School of MedicineSacramento
  2. 2.M.I.N.D. InstituteUniversity of California, Davis Health SystemSacramento
  3. 3.Department of PediatricsRush University Medical CenterChicago
  4. 4.Department of Neurological SciencesRush University Medical CenterChicago
  5. 5.Department of BiochemistryRush University Medical CenterChicago

Personalised recommendations